|
WO2010037838A2
(en)
*
|
2008-10-01 |
2010-04-08 |
Micromet Ag |
Cross-species-specific single domain bispecific single chain antibody
|
|
SG194399A1
(en)
*
|
2008-10-01 |
2013-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
WO2010037837A2
(en)
*
|
2008-10-01 |
2010-04-08 |
Micromet Ag |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
ME02485B
(me)
*
|
2008-10-01 |
2017-02-20 |
Amgen Res Munich Gmbh |
Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
|
|
SG190726A1
(en)
|
2010-11-30 |
2013-07-31 |
Chugai Pharmaceutical Co Ltd |
Cytotoxicity-inducing therapeutic agent
|
|
US20140161800A1
(en)
|
2011-04-22 |
2014-06-12 |
John W. Blankenship |
Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
|
|
UA115402C2
(uk)
*
|
2011-05-21 |
2017-10-25 |
Макродженікс, Інк. |
Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
GB201303308D0
(en)
*
|
2013-02-25 |
2013-04-10 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
ES2776706T3
(es)
*
|
2013-07-05 |
2020-07-31 |
Genmab As |
Anticuerpos contra CD3 humanizados o quiméricos
|
|
CA2918795A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
|
JP6449295B2
(ja)
|
2013-12-17 |
2019-01-09 |
ジェネンテック, インコーポレイテッド |
抗cd3抗体および使用方法
|
|
TN2017000532A1
(en)
|
2014-03-28 |
2019-04-12 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3.
|
|
WO2015156268A1
(ja)
|
2014-04-07 |
2015-10-15 |
中外製薬株式会社 |
免疫活性化抗原結合分子
|
|
CN106459954A
(zh)
|
2014-05-13 |
2017-02-22 |
中外制药株式会社 |
用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
|
|
CN106661119A
(zh)
|
2014-07-01 |
2017-05-10 |
辉瑞公司 |
双特异性异二聚化双抗体及其用途
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
CN107108738A
(zh)
|
2014-07-25 |
2017-08-29 |
西托姆克斯治疗公司 |
抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
|
|
WO2016016859A1
(en)
*
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
EA201790342A1
(ru)
|
2014-08-08 |
2017-07-31 |
ЭЛЕКТОР ЭлЭлСи |
Антитела к trem2 и способы их применения
|
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN107406512A
(zh)
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
HK1252158A1
(zh)
*
|
2015-05-01 |
2019-05-17 |
Genentech, Inc. |
掩蔽抗cd3抗体和使用方法
|
|
CA2985125A1
(en)
*
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
JP6841754B2
(ja)
*
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
AU2016271113B2
(en)
|
2015-05-29 |
2022-09-08 |
Amphivena Therapeutics, Inc. |
Methods of using bispecific CD33 and CD3 binding proteins
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
HK1251480A1
(zh)
|
2015-09-21 |
2019-02-01 |
Aptevo Research And Development Llc |
Cd3结合多肽
|
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
CN108699136B
(zh)
*
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
PL3411404T3
(pl)
|
2016-02-03 |
2023-02-13 |
Amgen Research (Munich) Gmbh |
Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
|
|
US11414497B2
(en)
|
2016-04-13 |
2022-08-16 |
Orimabs Ltd. |
Anti-PSMA antibodies and use thereof
|
|
EP3468586B1
(en)
|
2016-06-14 |
2024-08-07 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
US11613572B2
(en)
|
2016-06-21 |
2023-03-28 |
Teneobio, Inc. |
CD3 binding antibodies
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
KR20240044520A
(ko)
*
|
2016-09-14 |
2024-04-04 |
테네오원, 인코포레이티드 |
Cd3 결합 항체
|
|
US10689461B2
(en)
|
2016-09-15 |
2020-06-23 |
Novimmune Sa |
Antibody dual display dual compositions and methods of use thereof
|
|
IL265800B2
(en)
*
|
2016-10-11 |
2023-10-01 |
Agenus Inc |
Anti-LAG-3 antibodies and methods of using them
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
EP4215548A1
(en)
|
2016-12-21 |
2023-07-26 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
US11834506B2
(en)
|
2017-02-08 |
2023-12-05 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
|
TWI676681B
(zh)
*
|
2017-03-29 |
2019-11-11 |
臺北醫學大學 |
具抗原專一性的t細胞及其用途
|
|
CN117866097A
(zh)
|
2017-06-20 |
2024-04-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
CN118146370A
(zh)
|
2017-06-20 |
2024-06-07 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
TWI811229B
(zh)
|
2017-08-03 |
2023-08-11 |
美商阿列克特有限責任公司 |
抗trem2抗體及其使用方法
|
|
AU2018347607B2
(en)
|
2017-10-14 |
2025-08-21 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
WO2019094637A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
EA202091557A1
(ru)
|
2017-12-22 |
2020-11-18 |
Тенеобио, Инк. |
Антитела, содержащие только тяжелые цепи, которые связываются с cd22
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
ES2986967T3
(es)
|
2018-02-08 |
2024-11-13 |
Dragonfly Therapeutics Inc |
Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
MA51793A
(fr)
|
2018-02-08 |
2020-12-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
|
|
BR112020016939A2
(pt)
|
2018-02-20 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso
|
|
CN120399075A
(zh)
|
2018-03-14 |
2025-08-01 |
诺维莫尼公司 |
抗-CD3ε抗体及其应用方法
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
|
US11976131B2
(en)
*
|
2018-07-31 |
2024-05-07 |
Heidelberg Pharma Research Gmbh |
Humanized antibodies against PSMA
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
KR102835308B1
(ko)
|
2018-08-08 |
2025-07-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
SG11202100883SA
(en)
|
2018-08-08 |
2021-02-25 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
PE20220142A1
(es)
|
2019-04-05 |
2022-01-27 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
CN110156890B
(zh)
*
|
2019-04-09 |
2021-02-02 |
苏州大学 |
Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
|
|
EP3983438A1
(en)
|
2019-06-14 |
2022-04-20 |
TeneoBio, Inc. |
Multispecific heavy chain antibodies binding to cd22 and cd3
|
|
WO2021004400A1
(zh)
*
|
2019-07-06 |
2021-01-14 |
苏州克睿基因生物科技有限公司 |
一种表达cd3抗体受体复合物的免疫细胞及其用途
|
|
CA3146341A1
(en)
*
|
2019-07-30 |
2021-02-04 |
Aaron L. Kurtzman |
Bispecific anti lrrc15 and cd3epsilun antibudies
|
|
TWI897903B
(zh)
|
2019-12-13 |
2025-09-21 |
美商建南德克公司 |
抗ly6g6d抗體及其使用方法
|
|
BR112022013725A2
(pt)
|
2020-01-13 |
2022-10-11 |
Aptevo Res & Development Llc |
Formulações para agentes terapêuticos proteicos
|
|
IL294461A
(en)
|
2020-01-13 |
2022-09-01 |
Aptevo Res & Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
EP4240766A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
AU2021374592A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
PE20231860A1
(es)
|
2020-11-06 |
2023-11-21 |
Amgen Inc |
Moleculas de union a antigeno biespecificas con multiples dianas de selectividad aumentada
|
|
EP4259193A4
(en)
*
|
2020-12-09 |
2025-01-15 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
WO2022125583A1
(en)
*
|
2020-12-09 |
2022-06-16 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
|
|
US12377144B2
(en)
|
2021-03-03 |
2025-08-05 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
EP4341291A1
(en)
|
2021-05-21 |
2024-03-27 |
Aptevo Research and Development LLC |
Dosing regimens for protein therapeutics
|
|
CN118946583A
(zh)
|
2022-03-21 |
2024-11-12 |
美国安进公司 |
用t细胞接合分子治疗前列腺癌的联合治疗方法
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|